- Global Pharma News & Resources

Meadowhawk Biolabs Launches Biotech/Pharma CRO on Two Coasts

BOSTON & SAN FRANCISCO--(BUSINESS WIRE)--Meadowhawk Biolabs, Inc., a contract research organization (CRO) formed to provide bioanalytical, pharmacokinetic and pharmacological services to biotechnology and pharmaceutical companies, is pleased to announce its launch of operations in the Boston and San Francisco areas.

Founded in 2021 by industry veterans who have worked together for many years, Meadowhawk Biolabs serves companies in all therapeutic areas, according to Jim Jersey, the Meadowhawk CEO.

“As a group of dedicated professionals, we apply scientific insights and advances from biology, industrial engineering, information technology and other fields to advance our clients’ drug discovery and development,” Jersey said. “Innovative process engineering enables us to deliver results with incomparable speed and reliability. And it empowers our employees to add value where it counts.”

“We are dedicated to forming long term, mutually beneficial relationships with our customers and to efficiently and interactively fulfilling the needs of even the smallest startup.”

With laboratory and office facilities in Marlboro, Massachusetts and Hayward, California, the company, embedded in life science hubs on both US coasts, offers customers the advantages of rapid service and proximity.

Meadowhawk Biolabs will roll out its services in three stages.

  • Early 2022: Bioanalytical services to support small molecule therapeutics and biomarkers (LC/MS).
  • Mid-2022: In-vivo rodent pharmacokinetic services and non-GLP large molecule bioanalytical services (Immunoanalytical).
  • Early 2023: GLP large molecule bioanalytic services (Immunoanalytical) and in-vivo rodent oncology pharmacology services.

Meadowhawk Biolabs is funded by private equity investors and by its operational founders.

Its operational founders, who have all held senior-level positions in major companies, worked together at Agilux Laboratories, Inc., in Worcester MA, before Agilux was acquired by Charles River Labs in 2016.

Meadowhawk Biolabs operational founders include:

CEO: Jim Jersey, Ph.D.
Executive Vice President & General Manager, CA site: Xin Zhang, Ph.D.
Vice President Sales & Marketing: Mary Ann Gallo, M.S.
Vice President IT & Operations: Brian Lilley, B.S.
Vice President Finance & Administration: Jessica Sullivan, M.S.
Special Advisor: Steve Guyan, M.S.

TAGLINE: Meadowhawk Biolabs is a bicoastal contract research organization formed to provide bioanalytical, pharmacokinetic and pharmacological laboratory services to companies involved in drug discovery and development. With operations in the Boston and San Francisco life science hubs, Meadowhawk Biolabs offers rapid, reliable service and proximity to its customers.

Engage. Empower. Exceed.


Mary Ann Gallo
Vice President Sales & Marketing

Editor Details

  • Company:
    • Businesswire
Last Updated: 08-Mar-2022